FDA-Cleared Sepsis Panel Now Flags Resistance Genes

QIAstat-Dx BCID GN Plus AMR PanelWhat to know

30-second read

For Infectious Disease · Pathology · Emergency Medicine

Who

Hospitalized adults with a blood culture that has just turned positive for gram-negative bacteria — the leading cause of bloodstream infection and sepsis.

What it detects

13 gram-negative pathogen targets (E. coli, Klebsiella, Pseudomonas and others) plus 18 antimicrobial-resistance genes, from the same positive culture.

Evidence

Independent evaluation (174 cultures): beta-lactam resistance genes were highly predictive of phenotype (ctx-m/ampC 100%/100%); non-beta-lactam prediction was more variable.

Workflow fit

Runs on the same QIAstat-Dx cartridge as the gram-positive/fungal panel cleared in August — about an hour to result, on hardware a lab may already own.

Key consideration

A resistance gene is a genetic predictor, not a phenotypic susceptibility result — confirm with culture-based testing before finalizing targeted therapy.

Availability

FDA-cleared 24 September 2026 (510(k) K262168); already marketed in Europe under CE-IVDR. QIAGEN has not published U.S. pricing or a CPT/PLA code.

Practice impactConsider for stewardship workflows

Fits into an existing blood-culture workflow without new hardware for a lab that already runs QIAstat-Dx. Treat its resistance calls as a same-hour hypothesis to act on, not a final susceptibility result.

Read the full physician analysis

Full analysis · 8 min readQIAGEN clearance announcement · FDA 510(k) K262168 · independent RUO-kit evaluation (PMC11633170)

FDA cleared QIAGEN’s QIAstat-Dx BCID GN Plus AMR Panel on 24 September 2026 (510(k) K262168, announced by the company 28 September), completing a two-panel menu that now covers both gram-negative and gram-positive bloodstream infection from a single QIAstat-Dx cartridge. The clinical question the clearance itself does not answer is the one that matters at the bedside: how much should a physician trust a genetic resistance call returned in an hour, against the culture-based susceptibility result that will not arrive for one to three more days?

From a positive culture to a hypothesis in an hour

QIAGEN’s QIAstat-Dx is a syndromic PCR platform already running respiratory, gastrointestinal and meningitis/encephalitis panels in hospital labs in more than 100 countries. The new panel loads directly from a positive blood culture — no isolation or subculture step — and returns, in about an hour, identification of 13 gram-negative pathogen targets alongside 18 genetic markers associated with antimicrobial resistance. It completes a menu QIAGEN built in stages: the companion BCID GPF Plus AMR Panel, covering gram-positive bacteria and fungi, cleared FDA on 10 August 2026 (K254194). Together the two panels cover 33 pathogen targets and 28 resistance markers on one instrument, which matters operationally for a microbiology lab that already owns a QIAstat-Dx analyzer: bloodstream infection testing is a new menu, not new capital equipment.

The clinical logic is familiar to anyone who has managed a septic patient: broad-spectrum empiric antibiotics start the moment a blood culture turns positive, before a lab can say which organism is responsible or whether it resists the drug already running. Conventional culture-based identification and phenotypic susceptibility testing takes one to three additional days. An hour-long genetic readout cannot replace that process, but it can narrow the range of reasonable choices far sooner — which is the entire premise behind pairing identification with resistance markers in the same run, rather than ordering susceptibility testing as a separate, slower step.

What the evidence actually shows

The most directly relevant evidence on this specific panel comes from an independent evaluation of the QIAstat-Dx BCID GN and GPF research-use-only kits — the pre-clearance versions of these panels — against routine laboratory testing as the reference standard, in 174 monomicrobial positive blood cultures tested between November 2023 and January 2024. The evaluation found the kits reliably identified on-target pathogens, and that resistance-gene concordance with phenotypic results depended heavily on drug class. Beta-lactam resistance markers were strongly predictive: the combination of ctx-m and ampC genes was 100% sensitive and 100% specific for identifying third-generation cephalosporin resistance in E. coli and Klebsiella pneumoniae, and tem/shv markers for aminopenicillin resistance in E. coli ran 94.7% sensitive and 95.8% specific. The evaluation’s own conclusion was blunter outside that drug class: prediction of resistance for non-beta-lactam antimicrobials was more variable — a genetic marker is a strong lead on a beta-lactam, and a weaker one on other drug classes a stewardship team may be counting on.

On the separate question of whether faster identification actually changes what a physician prescribes, the published evidence is about the broader class of rapid blood-culture-identification panels — principally bioMérieux’s FilmArray and GenMark/Roche’s ePlex systems — not QIAstat-Dx specifically, and it does not point one direction. A Veterans Health Administration multicenter study of more than 4,100 patients found BioFire FilmArray BCID2 implementation associated with a modest but statistically significant rise in early antimicrobial de-escalation, from 34.6% to 38.1% of eligible patients. A retrospective cohort study at Grady Health System in Atlanta found GenMark ePlex BCID use cut the median time to optimal antimicrobial therapy from 72.1 to 43.4 hours, and time to de-escalation of anti-MRSA agents from 46.7 to 27.7 hours. But a quasi-experimental study at Mayo Clinic in Phoenix, comparing cohorts before and after BioFire BCID implementation, found the panel cut time to organism identification dramatically — 27.1 hours to 3.3 hours — without producing a statistically significant change in time to first appropriate escalation or de-escalation for either gram-positive or gram-negative infections. The pattern across these studies is consistent with what antimicrobial-stewardship literature generally reports: a faster result changes prescribing reliably only where an active stewardship program is built to act on it quickly; the test alone does not do that work.

QIAstat-Dx against other rapid bloodstream-infection panels

	QIAstat-Dx BCID GN+GPF (QIAGEN)	FilmArray BCID2 (bioMérieux)	T2Bacteria (T2 Biosystems)
Turnaround	~1 hour	~1 hour	~3–5 hours
Sample required	Positive blood culture	Positive blood culture	Whole blood — no culture wait
AMR markers included	28 genetic markers (both panels)	10 genetic markers	Not applicable
Replaces phenotypic susceptibility?	No — genetic predictor only	No — genetic predictor only	No identification or resistance data

From each company’s own labeling and published literature; not a head-to-head clinical comparison. Prescribe and stewardship-protocol from validated local data, not this table.

Where the call still needs a human

The practical discipline this panel asks of a physician and a microbiology lab together is to treat its output as two different kinds of information. Pathogen identification from a positive culture is a well-established use of multiplex PCR, with high concordance against standard culture methods in QIAGEN’s own clearance data and in the independent evaluation above. Resistance-gene detection is a different claim: it reports the presence of a genetic sequence associated with resistance, not a measured minimum inhibitory concentration. Where that distinction bites hardest is exactly where antimicrobial stewardship teams spend the most attention — non-beta-lactam resistance, where the independent evaluation found prediction “more variable,” and in any organism carrying a resistance mechanism the panel’s fixed gene list does not include. A negative result for a resistance gene is not evidence of susceptibility; it is evidence that this one panel found none of the markers it looks for.

Availability, cost and what remains unsettled

The gram-negative panel’s 510(k) number, not yet indexed when QIAGEN announced the clearance, is now posted in FDA’s public database as K262168, received 26 June 2026 and decided 24 September 2026 — a four-day gap between FDA’s decision date and the company’s own announcement that is typical of how these releases trail the agency’s internal record. Both panels launched in Europe under CE-IVDR before their U.S. clearances and are already commercially available there. QIAGEN has not published U.S. list pricing, a launch timeline into specific hospital systems, or a CPT or PLA code for either panel. That last gap is not a minor detail for a hospital lab deciding whether to adopt the menu: for an inpatient, molecular bloodstream-infection testing is typically bundled into the admission’s DRG payment rather than reimbursed as a separate line item, which shifts the adoption decision toward a lab’s own cost-per-test calculation and a stewardship program’s estimate of avoided drug-days, rather than toward a payer rate QIAGEN has not published.

What changes at the bedside

• For infectious disease and stewardship teams: a same-hour resistance signal to narrow empiric coverage — strong for beta-lactam calls, weaker for other drug classes — that still needs a protocol for acting on it quickly, not just receiving it quickly.
• For pathology and microbiology labs: a menu addition on existing QIAstat-Dx hardware, with a workflow decision about how a discordant genotype-phenotype result gets flagged and resolved before it reaches the chart.
• For emergency medicine and critical care: earlier pathogen-level information during the same admission a blood culture turns positive, without a change to how empiric therapy should start before any panel result is available.
• Not yet settled: U.S. pricing, a billing code, a published clinical-outcomes study on this specific panel, and how its resistance calls perform against organisms or mechanisms outside its 18-marker list.

Frequently asked questions

Does a resistance gene on this panel mean the organism is actually resistant?

Usually, but not always. An independent evaluation of the research-use kits found genetic markers for beta-lactam resistance (such as ctx-m and ampC for third-generation cephalosporin resistance) were 100% concordant with phenotypic susceptibility results, while prediction for non-beta-lactam drug classes was more variable. Treat a resistance call as a strong hypothesis to act on immediately, confirmed by the culture-based susceptibility result that follows in one to three days.

Does faster pathogen ID actually get patients onto the right antibiotic sooner?

Evidence is mixed and panel-dependent, not yet reported for this specific QIAGEN panel. Studies of other rapid blood-culture-ID panels found faster organism identification translated into measurably faster de-escalation at a Veterans Affairs medical center and at Grady Health System, but a Mayo Clinic Phoenix study found no significant change in time to escalation or de-escalation without active stewardship support built around the result.

Is this panel covered by Medicare or commercial insurance?

QIAGEN's clearance announcement does not cite a CPT or PLA code, and Regulatory News found none published for this panel independently. For an inpatient, the test is typically bundled into the admission's DRG payment rather than billed separately; outpatient or reference-lab billing would depend on a payer accepting whatever code the lab uses for multiplex PCR bloodstream-infection testing, which QIAGEN has not specified for this panel.